BACKGROUND: There is an increasing recognition of the potential value of cardiopulmonary exercise testing (CPX) in patients with pulmonary hypertension (PH). Key CPX characteristics in these patients include: (1) a diminished aerobic capacity; (2) an abnormally elevated minute ventilation-carbon dioxide production relationship; and (3) an abnormally diminished partial pressure of end-tidal carbon dioxide. Given the burgeoning number of original research investigations utilizing CPX in patients with PH, a summation of the presently available body of literature seems timely. METHODS: A literature search was conducted in pubmed using "cardiopulmonary exercise testing" and "pulmonary arterial hypertension" as key phrases. Only studies conducting exercise testing with simultaneous ventilatory expired gas analysis in subjects with a confirmed diagnosis of pulmonary arterial hypertension were included. Twenty-three investigations were included in this review. Nineteen of the investigations assessed cohorts with resting pulmonary arterial hypertension as the sole diagnosis. Two investigations assessed subjects with chronic obstructive pulmonary disease and pulmonary arterial hypertension: one assessed subjects with pulmonary fibrosis and pulmonary arterial hypertension, and another included groups with exercise-induced pulmonary arterial hypertension and resting pulmonary arterial hypertension. RESULTS: Collectively, these investigations indicate variables obtained from CPX: (1) reflect varying degrees of PH severity; (2) positively respond to several pharmacologic and surgical interventions; and (3) may provide prognostic value. CONCLUSIONS: Currently, CPX is not widely utilized in patients with PH. Although more research is required in a number of areas, the present evidence-based review indicates this exercise testing technique may provide valuable information in the PH population.
BACKGROUND: There is an increasing recognition of the potential value of cardiopulmonary exercise testing (CPX) in patients with pulmonary hypertension (PH). Key CPX characteristics in these patients include: (1) a diminished aerobic capacity; (2) an abnormally elevated minute ventilation-carbon dioxide production relationship; and (3) an abnormally diminished partial pressure of end-tidal carbon dioxide. Given the burgeoning number of original research investigations utilizing CPX in patients with PH, a summation of the presently available body of literature seems timely. METHODS: A literature search was conducted in pubmed using "cardiopulmonary exercise testing" and "pulmonary arterial hypertension" as key phrases. Only studies conducting exercise testing with simultaneous ventilatory expired gas analysis in subjects with a confirmed diagnosis of pulmonary arterial hypertension were included. Twenty-three investigations were included in this review. Nineteen of the investigations assessed cohorts with resting pulmonary arterial hypertension as the sole diagnosis. Two investigations assessed subjects with chronic obstructive pulmonary disease and pulmonary arterial hypertension: one assessed subjects with pulmonary fibrosis and pulmonary arterial hypertension, and another included groups with exercise-induced pulmonary arterial hypertension and resting pulmonary arterial hypertension. RESULTS: Collectively, these investigations indicate variables obtained from CPX: (1) reflect varying degrees of PH severity; (2) positively respond to several pharmacologic and surgical interventions; and (3) may provide prognostic value. CONCLUSIONS: Currently, CPX is not widely utilized in patients with PH. Although more research is required in a number of areas, the present evidence-based review indicates this exercise testing technique may provide valuable information in the PH population.
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Paul Chase; Daniel Bensimhon; Lawrence P Cahalin; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman Journal: Congest Heart Fail Date: 2012-04-26
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie Journal: Expert Rev Respir Med Date: 2011-04 Impact factor: 3.772
Authors: Cory R Trankle; Justin M Canada; Dinesh Kadariya; Roshanak Markley; Horacio Medina De Chazal; Janet Pinson; Adam Fox; Benjamin W Van Tassell; Antonio Abbate; Daniel Grinnan Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405
Authors: Paul R Woods; Robert P Frantz; Bryan J Taylor; Thomas P Olson; Bruce D Johnson Journal: J Heart Lung Transplant Date: 2011-05-31 Impact factor: 10.247
Authors: Hilary F Armstrong; P Christian Schulze; Matthew Bacchetta; Wilawan Thirapatarapong; Matthew N Bartels Journal: Respirology Date: 2014-05-06 Impact factor: 6.424
Authors: Leighton Chan; Lisa M K Chin; Michelle Kennedy; Joshua G Woolstenhulme; Steven D Nathan; Ali A Weinstein; Gerilynn Connors; Nargues A Weir; Bart Drinkard; James Lamberti; Randall E Keyser Journal: Chest Date: 2013-02-01 Impact factor: 9.410